P166 Venous thromboembolism with inflammatory bowel disease
L. Mouelhi*, O. Daboussi, M. Ben Khelifa, F. Houissa, K. El Jery, Y. Said, M. Salem, R. Dabbech, T. Najjar
Charles Nicolle Hospital, Gastroenterology, Tunis, Tunisia
Venous thrombosis and thromboembolism appear to be increased in patients with inflammatory bowel disease (IBD). Prophylactic use of anticoagulants should be reviewed in an individual patient after evaluation of the risks, such as haemorrhage, compared with potential benefits.
Objective: To investigate the prevalence and risk factors for thromboembolism in IBD.
We conducted a retrospective study including all patients hospitalised for IBD in the Gastroenterology Department between January 1, 2000 and January 9, 2015. Characterisation of the population consisted of the variables IBD (type, location, behaviour, and therapy) and thromboembolic event (location and associated risk factors).
In total, 295 patients were included, 47% male, mean age 33 ± 12 years; ulcerative colitis 32% (E1-20%, E2-43%, and E3-37%), and 68% with Crohn’s disease (L1-34%, L2-43%, L3-23%, B1-46%, B2-33%, and B3-21%). Medication included aminosalicylate 24%, corticosteroids (52%), thiopurines (29%), and anti-tumour necrosis factor (TNF) α (8%). A venous thromboembolism occurred in 12 patients (4%), 7 men and 5 women. Moreover, 7 patients had Crohn’s disease and 5 had ulcerative colitis. It was a deep thrombosis in 7 patients and associated with pulmonary embolism in 1, as well as 2 with cerebral venous sinus thrombosis, a portal vein thrombosis in 2, and a jugular vein thrombosis in 1. IBD was active in all patients at thromboembolic event. In addition, 5 patients had other concomitant risk factors.
In our study, the prevalence of venous thromboembolism was 4% amongst patients with IBD. Deep vein thrombosis was the most frequent thromboembolic event. All cases occurred during the active phase of IBD.